n.a. (HSP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
First Solar, RIM: Analysts' New Ratings

First Solar, RIM: Analysts' New Ratings

First Solar downgraded at Kaufman from Buy to Hold. Research in Motion upgraded at Morgan Stanley from Underweight to Equal-weight.

Hospira CEO Discusses Q4 2010 Earnings Call Transcript

Hospira CEO Discusses Q4 2010 Earnings Call Transcript

Hospira CEO Discusses Q4 2010 Earnings Call Transcript

The Top FDA Drug Approval Pickers

The Top FDA Drug Approval Pickers

Meet the three winners of TheStreet's FDA Drug Approval Contest.

Hospira, Inc CEO Discusses Q3 2010 - Earnings Call Transcript

Hospira, Inc CEO Discusses Q3 2010 - Earnings Call Transcript

Hospira, Inc CEO Discusses Q3 2010 - Earnings Call Transcript

Play TheStreet's FDA Drug-Approval Contest

Try to correctly predict the approval decisions made by the U.S. Food and Drug Administration on 11 new drugs in October.

Hospira And Smiths Medical To Co-Promote Infusion Pumps And Develop A Standardized Safety Monitoring And Reporting Solution Across Infusion Systems

Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, and Smiths Medical, a leading global medical device manufacturer, today announced a commercial...

Hospira, Inc. Q2 2010 Earnings Call Transcript

Hospira, Inc. Q2 2010 Earnings Call Transcript

5 Stocks Setting New 52-Week Highs

When it comes to 52-week highs, there are sometimes as many reasons to be wary as there are reasons to think the profits will keep flowing.

Javelin Pharma, Spire: Volume Movers

Javelin Pharma, Spire: Volume Movers

Several stocks, including Javelin Pharmaceuticals, were poised to move on above-average volume Tuesday.

The 5 Dumbest Things on Wall Street: May 28

The 5 Dumbest Things on Wall Street: May 28

Javelin's unravelin'; DreamWorks' nightmare; EMC pays to play; Perrigo needs a maid; Disney's dopey duo.

The Five Dumbest Things on Wall Street: May 28

Javelin's unravelin'; DreamWorks' nightmare; EMC pays to play; Perrigo needs a maid; Disney's dopey duo.

The Rational Optimist, Global Cash CEO, Mid Cap Stars

Gregg Greenberg breaks down today's market action with guests Matt Ridley, author of The Rational Optimist, Scott Betts, CEO of Global Cash Access and Pat Dunkerley, portfolio manager for the Scout Mid Cap fund.

Global Sources, Hauppauge Digital: Midday Volume Plays

Several stocks trading near $5, including Global Sources, were moving on above-average volume Wednesday.

Hospira, Inc. Q1 2010 Earnings Call Transcript

Hospira, Inc. Q1 2010 Earnings Call Transcript

Javelin Pharmaceuticals, EDAP: Early Volume Plays

Several stocks trading near $5 were moving on above-average volume during Monday's session.

Recalls: Anesthetic Medications

Recalls: Anesthetic medications

Chemotherapy Drug Sales Boost Hospira 3Q Profit

Chemotherapy Drug Sales Boost Hospira 3Q Profit

Hospira profit climbs on sales of generic chemotherapy treatment and other specialty drugs

CIT Craziness, Hospira's CEO And Small Caps

CIT Craziness, Hospira's CEO And Small Caps

Guests include David Levy, economist from the Jerome Levy Forecasting Center, Chris Begley, CEO of Hospira and Carl Gardiner, portfolio manager for the Cullen Small Cap Value Fund.

Hospira Boosts Outlook Citing Performance

Hospira boosts 2009 profit outlook after highlighting sales, operating performance

Hospira Says FDA Approves 6 More Doses Of Heparin

Hospira Says FDA Approves 6 More Doses Of Heparin

Hospira says FDA approved 6 new doses and concentrations of blood thinning drug heparin

Options Recap: Cisco, Dish, Hospira

Options Recap: Cisco, Dish, Hospira

Cisco's quarterly earnings report next week could have broad impact on the market.

Sussing Out the Second Quarter

This health care name reported an earnings beat, as well as announced a new distribution deal.

Hospira Shares Rise On Patent Decision

Hospira Shares Rise On Patent Decision

Hospira shares rise as court rules in its favor on patent dispute with Sanofi-Aventis

Moody's Upgrades Outlook On Hospira To 'Stable'

Moody's upgrades outlook on Hospira to 'Stable' on improved debt

Hospira 1Q Profit Doubles On Tax Benefit

Hospira's 1st-quarter profit doubles on hefty tax benefit, lower operating expenses

Total Jobless Benefit Rolls Top 5.5 Million

Total benefit rolls climb to record above 5.5M as new jobless claims also rise

Jobless Claims Set New Record

US jobless claims set new record for 9th straight week; economy worse than thought in 4Q

Total Jobless Benefit Rolls Top 5.5M

Total benefit rolls climb to record above 5.5M as new claims also rise

Jobless Rolls Swell Again As Recession Persists

Unemployment rolls grow for the 10th week in a row; glimmers of economic hope fade a bit

Ahead Of The Bell: 4Q GDP Final Revision

Wall Street expects fourth-quarter GDP to drop even more sharply in final revision